Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Glaxo’s Revolade Wins U.K. Cost Agency’s Backing

Dec. 18 (Bloomberg) -- GlaxoSmithKline’s Revolade wins backing of health-cost agency in draft guidance on treatment of a rare bleeding disorder after drugmaker agrees to sell it to state-run medical system at a discount. * Revolade is cost-effective for chronic immune

thrombocytopenic purpura in certain adults who have had

their spleens removed and those who haven’t responded to at

least one other therapy, National Institute for Health and

Clinical Excellence says in e-mailed statement * Decision reverses 2010 ruling that drug was too costly;

agency didn’t disclose size of discount Glaxo is offering

Story Link:NSN MF6JPN6JIJY2<GO>

For Related News and Information: First Word scrolling panel: FIRST<GO> First Word newswire: NH BFW<GO>

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.